All Merck KGaA articles
-
NewsMerck’s €10k synthesis competition will lab test routes
Pharma company offers €10,000 in prize money for retrosynthesis challenge that will bench test finalists’ proposals
-
ResearchScrutiny of SmartFlares raises questions over RNA probes
Merck Millipore technology for detecting specific RNAs may not live up to claims
-
BusinessDrug formula change infuriates French thyroid patients
Poor communication of changes to Merck KGaA’s levothyroxine has led to complaints of side effects
-
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project
-
BusinessFirst biomarker-driven approval exemplifies cancer immunotherapy progress
Landmark decision is latest step in field’s impressive – but not wholly untroubled – advance
-
BusinessMerck KGaA to buy Chematica
Retrosynthesis tool will gain computational muscle and integrate with Sigma–Aldrich catalogue
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
WebinarFrom milligrams to kilograms: synthetic chemistry following nature’s lead
This webinar covers the discovery of greener chemistry in academia and its adoption in both medicinal and process chemistry groups
-
BusinessCancer deals spread
AbbVie nabs antibody specialist Stemcentrx, while Sanofi pursues Medivation
-
BusinessCompanies clamour for CAR-T
Engineered immune cell therapies show promise in early cancer trials, prompting firms to compete for a foothold in the field
-
BusinessMerck KGaA to buy Sigma–Aldrich
$17bn acquisition expands Merck’s life science business and US presence, but it isn’t stepping back from drug development
-
-
Business
Merck KGaA snaps up electronic materials specialist
Firm looks to bolster R&D by acquiring AZ Electronic Materials
-
Business
Merck KGaA to cut 1100 German jobs
Company provides detail of restructuring programme announced in February
-
Business
Merck KGaA buys cell culture company
Biochrom makes cell culture media and buffer solutions